CytoKi Pharma

Værløse, Denmark Founded: 2019 • Age: 7 yrs
Therapeutics for epithelial-based diseases are developed and targeted.
Annual revenue - Latest available
Total funding $45.0M 2 rounds
Employees 4 Tracked headcount
Investors 4 Known backers
Products 1 Services tracked
Competitors 10 Brand Intelligence

About CytoKi Pharma

CytoKi Pharma is a company based in Værløse (Denmark) founded in 2019 by Rasmus Jorgensen. CytoKi Pharma has raised $45.02 million across 2 funding rounds from investors including Lundbeck Foundation, Seventure Partners and Ysios Capital. The company has 4 employees as of December 31, 2022. CytoKi Pharma offers products and services including CK-0045. CytoKi Pharma operates in a competitive market with competitors including Aclaris Therapeutics, Sana Biotechnology, Semma Therapeutics, Adocia and Altimmune, among others.

  • Headquarter Værløse, Denmark
  • Employees 4 as on 31 Dec, 2022
  • Founders Rasmus Jorgensen
  • Stage Minicorn
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Cytoki Pharma Aps
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    -$13.94 M (USD)
    -231
    as on Dec 31, 2022
  • EBITDA
    -$14.71 M (USD)
    -192
    as on Dec 31, 2022
  • Total Equity Funding
    $45.02 M (USD)

    in 2 rounds

  • Latest Funding Round
    $45 M (USD), Series A

    May 05, 2021

  • Investors
  • Employee Count
    4

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of CytoKi Pharma

CytoKi Pharma offers a comprehensive portfolio of products and services, including CK-0045.

Product name locked
Category locked
Primary

Long-acting IL-22 analogue for treating metabolic and inflammatory conditions

People of CytoKi Pharma

Headcount 1-10
Employee Profiles 5
Board Members and Advisors 9
Employee Profiles
People
Karsten Skydsgaard
Head of Non-Clinical Development
People
Dorte Waaben
Head, CMC
People
Anuj Madhok
Chief Business Officer

Unlock access to complete

Board Members and Advisors
people
Klaus Dugi
Board Member
people
Christian Elling
Board Member
people
Karen Wagner
Board Member
people
Annegret de Baey-Diepolder
Member Board Of Directors

Unlock access to complete

Funding Insights of CytoKi Pharma

CytoKi Pharma has successfully raised a total of $45.02M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $45 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in CytoKi Pharma

CytoKi Pharma has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Lundbeck Foundation, Seventure Partners and Ysios Capital.

All
Venture Fund
Investor Description Founded Year Domain Location
Life science companies are funded through venture capital investments.
Locked Locked Locked
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
Locked Locked Locked
Ysios Capital is recognized as a leading life sciences investor.
Locked Locked Locked
Premium access

Investor details for CytoKi Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by CytoKi Pharma

Investments
Premium access

Investment portfolio details for CytoKi Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - CytoKi Pharma

Premium access

Detailed financials for CytoKi Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cytoki Pharma Comparisons

CytoKi Pharma Primary company
Description
Therapeutics for epithelial-based diseases are developed and...
Location
Værløse, Denmark
Founded Year
2019
Annual Revenue
Not available
Net Profit
-$13.94 M (USD)
EBITDA
-$14.71 M (USD)
Employees
4
As of 2022
Premium access

Peer comparison for CytoKi Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of CytoKi Pharma

CytoKi Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Sana Biotechnology, Semma Therapeutics, Adocia and Altimmune, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel dermatologic therapies are developed for skin conditions.
Locked Locked Locked
Genetically engineered cell therapies are developed for multiple disorders.
Locked Locked Locked
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
Locked Locked Locked
Therapeutics for diabetes and obesity treatment are developed.
Locked Locked Locked
Vaccines for infectious diseases and solid tumors are developed.
Locked Locked Locked
Therapies for metabolic and orphan diseases are developed by Rezolute.
Premium access

Detailed competitors of CytoKi Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cytoki Pharma

Premium access

Complete news archive for CytoKi Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CytoKi Pharma

CytoKi Pharma was founded in 2019 and raised its 1st funding round 2 years after it was founded.

CytoKi Pharma is headquartered in Værløse, Denmark.

Rasmus Jorgensen is the current CEO of CytoKi Pharma. They have also founded this company.

CytoKi Pharma is a funded company, having raised a total of $45.02M across 2 funding rounds to date.

As of Dec 31, 2022, the latest employee count at CytoKi Pharma is 4.

CytoKi Pharma was founded in 2019 and is based in Vaerlose, Denmark. Operations focus on the biotechnology sector, where engineered biologics are developed to address epithelial-based diseases. The lead product employs IL22 to target non-hematopoietic epithelial and stromal cells. Tissue damage is reduced, repair is stimulated, inflammation is controlled, and fibrosis-free recovery is supported through promotion of cell survival, proliferation, and regeneration.

CytoKi Pharma's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.

CytoKi Pharma offers CK-0045.

CytoKi Pharma has 4 investors. Key investors include Lundbeck Foundation, Seventure Partners, Ysios Capital, and ND Capital.

The valuation of CytoKi Pharma is $5.64M as of Apr 2021.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available